Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects

NCT07697846 is registered in ClinicalTrials.gov with Beijing QL Biopharmaceutical Co.,Ltd as lead sponsor.

NCT NCT07697846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07697846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects
Lead sponsor
Beijing QL Biopharmaceutical Co.,Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 18, 2026
Completion date
March 24, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight, obesity